Taking Stock of Trade Secrets to Prepare for Future Litigation

Generative artificial intelligence creates content and work efficiencies but also comes with legal pitfalls. Mintz Venture Capital & Emerging Companies Practice Co-chair Jeremy Glaser and Associate Lorena Niebla look at the technology's potential uses as well as risks related to data privacy, intellectual property, and more.

Mintz represented ArriVent Biopharma in a $155 Million Series B financing led by Sofinnova Investments and General Catalyst to fund studies of the company's EGFR kinase inhibitor furmonertinib. Members Ed Pease and Private Equity Practice Co-Chair Matthew Simpson led the Mintz team's work on the transaction.

Deal activity remains high for our Energy & Sustainability Practice, building on the momentum of last year’s record of 57 transactions with an aggregate deal value of $4.6 billion. Global investment into energy transition and climate technology drove our work for clients like NET Power, Nuvve Corporation, and Aspen Aerogels.

BOSTON, TORONTO – Mintz  is pleased to announce its expansion into Canada with the opening of a Toronto office, launched by a team of highly regarded and industry-leading attorneys. The new office will add depth and breadth to Mintz’s global Life Sciences practice and will further expand the firm’s strong Private Equity, Capital Markets, and Pensions and Employment practices.

Mintz’s new Women’s Health and Technology Practice brings together attorneys from our transactional, intellectual property, health care, FDA regulatory, and litigation teams to serve FemTech and other life sciences clients. The practice advises companies, entrepreneurs, and investors focused on addressing unmet needs in women’s health.